Aliases & Classifications for Prostatic Hypertrophy

MalaCards integrated aliases for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 12 14 69
Benign Prostatic Hypertrophy 69
Prostatic Hyperplasia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11132

Summaries for Prostatic Hypertrophy

MalaCards based summary : Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to prostate cancer and prostatitis, and has symptoms including prostatism An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Pathways in cancer and EGF/EGFR Signaling Pathway. The drugs Alfuzosin and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, liver and heart, and related phenotypes are immune system and endocrine/exocrine gland

Related Diseases for Prostatic Hypertrophy

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 28.1 AR CYP19A1 EGF EGFR ESR1 FGF8
2 prostatitis 10.9
3 hole retinal cyst 10.7 AR KLK3
4 endometriosis 10.7 AR KLK3
5 ulceroglandular tularemia 10.7 AR ESR1
6 mucinous adenocarcinoma 10.7 AR KLK3
7 osteopathia striata with cranial sclerosis 10.7 AR CYP19A1
8 bartholin's gland benign neoplasm 10.6 ESR1 PGR
9 central nervous system organ benign neoplasm 10.6 ESR1 PGR
10 gallbladder leiomyoma 10.6 ESR1 PGR
11 lung adenoma 10.6 ESR1 PGR
12 glaucoma, hereditary 10.6 ESR1 PGR
13 vitamin d-dependent rickets type ii 10.6 AR ESR1
14 fallopian tube benign neoplasm 10.6 ESR1 PGR
15 paranasal sinus disease 10.6 ESR1 PGR
16 dartoic leiomyoma 10.6 ESR1 PGR
17 urinary bladder inverted papilloma 10.6 ESR1 PGR
18 spinal cancer 10.6 ESR1 PGR
19 deafness, autosomal dominant 8/12 10.6 ESR1 PGR
20 gastrojejunal ulcer 10.6 AR CYP19A1
21 intestinal perforation 10.6 ESR1 PGR
22 epilepsy, idiopathic generalized 11 10.6 AR CYP19A1
23 superficial basal cell carcinoma 10.6 ESR1 PGR
24 pineal region meningioma 10.6 ESR1 PGR
25 bladder colloid adenocarcinoma 10.6 ESR1 PGR
26 ovarian mesodermal adenosarcoma 10.6 ESR1 PGR
27 berk-tabatznik syndrome 10.6 CYP19A1 PGR
28 endophthalmitis 10.6 ESR1 PGR
29 panophthalmitis 10.6 CYP19A1 PGR
30 subglottis neoplasm 10.6 CYP19A1 ESR1
31 chest wall lymphoma 10.6 ESR1 PGR
32 cutaneous mucoepidermoid carcinoma 10.5 ESR1 PGR
33 retinal detachment 10.5 ESR1 PGR
34 holoprosencephaly 6 10.5 ESR1 PGR
35 retinitis pigmentosa 20 10.5 ESR1 PGR
36 carbuncle 10.5 AR ESR1
37 bowman's membrane folds or rupture 10.5 AR PGR
38 urethra clear cell adenocarcinoma 10.5 ESR1 PGR
39 parkinson disease, juvenile, type 2 10.5 CYP19A1 ESR1
40 rectal neoplasm 10.5 ESR1 PGR
41 adenosine monophosphate deaminase 1 deficiency 10.5 ESR1 PGR
42 organ system benign neoplasm 10.5 ESR1 PGR
43 cartilage cancer 10.5 ESR1 PGR
44 aromatase excess syndrome 10.5 CYP19A1 ESR1
45 spiradenoma 10.5 AR PGR
46 glioblastoma proneural subtype 10.4 AR CYP19A1 KLK3
47 infratentorial cancer 10.4 AR CYP19A1 KLK3
48 prostate small cell carcinoma 10.4 AR KLK3
49 hypersensitivity reaction type iii disease 10.4 ESR1 PGR
50 benign fibrous mesothelioma 10.4 EGF ESR1

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN): (show top 50) (show all 52)


Acute Cystitis Acute Kidney Failure
Anthracosis Asbestosis
Balanoposthitis Bladder Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Cystitis Cystica Epididymo-Orchitis
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Hydronephrosis
Infected Hydrocele Interstitial Cystitis
Ischemic Heart Disease Kidney Disease
Left Bundle Branch Hemiblock Lipoma of Spermatic Cord
Low Compliance Bladder Nephrolithiasis, Type I
Neurogenic Bladder Parkinson Disease, Late-Onset
Pelvic Varices Penile Disease
Peyronie's Disease Pinta Disease
Pneumoconiosis Postinflammatory Pulmonary Fibrosis
Prostate Calculus Prostate Cancer
Prostate Carcinoma in Situ Prostate Disease
Prostatitis Prostatocystitis
Renal Pelvis Carcinoma Right Bundle Branch Block
Silicosis Spermatocele
Ureter Cancer Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Bladder Cancer Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to Prostatic Hypertrophy

Symptoms & Phenotypes for Prostatic Hypertrophy

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.02 AR CYP19A1 EGF EGFR ESR1 FGF8
2 endocrine/exocrine gland MP:0005379 10.01 PCNA PGR AR CYP19A1 EGF EGFR
3 cardiovascular system MP:0005385 10 ADRA1A AR CYP19A1 EGFR ESR1 FGF8
4 digestive/alimentary MP:0005381 9.91 AR CYP19A1 EGF EGFR ESR1 FGF8
5 adipose tissue MP:0005375 9.88 AR CYP19A1 EGFR ESR1 PCNA
6 muscle MP:0005369 9.8 ADRA1A AR CYP19A1 EGFR ESR1 FGF8
7 limbs/digits/tail MP:0005371 9.72 AR EGFR ESR1 FGF8 PGR
8 normal MP:0002873 9.7 AR CYP19A1 EGF EGFR ESR1 FGF8
9 renal/urinary system MP:0005367 9.43 EGFR ESR1 FGF8 ADRA1A AR CYP19A1
10 reproductive system MP:0005389 9.23 AR CYP19A1 EGF EGFR ESR1 FGF8

Drugs & Therapeutics for Prostatic Hypertrophy

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
2
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 1 106133-20-4 129211
3 Mirabegron Approved Phase 4 223673-61-8
4
Silodosin Approved Phase 4 160970-54-7
5
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Dihydrotachysterol Approved Phase 4 67-96-9 5281010 5311071
8
Dutasteride Approved, Investigational Phase 4,Phase 3 164656-23-9 152945 6918296
9
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
10
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
11
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
12
Dihydrotestosterone Illicit Phase 4 521-18-6 10635
13 Adrenergic Agents Phase 4,Phase 3
14 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
15 Adrenergic alpha-Antagonists Phase 4,Phase 3
16 Adrenergic Antagonists Phase 4,Phase 3
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
18 Anesthetics Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic beta-3 Receptor Agonists Phase 4
21 Adrenergic beta-Agonists Phase 4
22
Atracurium Phase 4 64228-79-1 47319
23 Cholinergic Agents Phase 4,Phase 3,Phase 2
24 Cholinergic Antagonists Phase 4
25 Neuromuscular Agents Phase 4,Phase 3,Phase 2
26 Neuromuscular Blocking Agents Phase 4
27 Neuromuscular Nondepolarizing Agents Phase 4
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
29 Muscarinic Antagonists Phase 4
30 Solifenacin succinate Phase 4 242478-38-2
31 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
32 Anabolic Agents Phase 4,Phase 2
33 Androgens Phase 4,Phase 3,Phase 2
34 Antineoplastic Agents, Hormonal Phase 4,Phase 2
35 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
36 Hormones Phase 4,Phase 3,Phase 1,Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
38 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
39 Testosterone 17 beta-cypionate Phase 4,Phase 2
40
Testosterone enanthate Phase 4,Phase 2 315-37-7 9416
41 Testosterone undecanoate Phase 4,Phase 2
42 Antihypertensive Agents Phase 4,Phase 3
43
Cetrorelix Approved, Investigational Phase 3 120287-85-6 16129715 25074887
44
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
45
Finasteride Approved Phase 3,Phase 1,Phase 2 98319-26-7 57363
46
Tadalafil Approved, Investigational Phase 3,Phase 2,Phase 1 171596-29-5 110635
47
Magnesium oxide Approved Phase 3 1309-48-4 14792
48
Metformin Approved Phase 3 657-24-9 14219 4091
49
Inulin Approved, Nutraceutical Phase 3 9005-80-5 24763
50 Fertility Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 89)

id Name Status NCT ID Phase Drugs
1 Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy Completed NCT00542165 Phase 4 Alfuzosin
2 A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) Completed NCT02656173 Phase 4 Mirabegron;Placebo
3 Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH Completed NCT01260129 Phase 4 Silodosin;Silodosin
4 Effect of Deep BLock on Intraoperative Surgical Conditions Completed NCT01631149 Phase 4 Surgical block (rocuronium; atracurium/mivacurium);Surgical block (rocuronium; atracurium/mivacurium)
5 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
6 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
7 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
8 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4 Dutasteride
9 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
10 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin
11 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
12 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
13 Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair Enrolling by invitation NCT02958878 Phase 4 Tamsulosin;Placebo Oral Capsule
14 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Completed NCT00663858 Phase 3 Cetrorelix 78+78;Cetrorelix 78 + Placebo
15 The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate Completed NCT00427219 Phase 2, Phase 3 Ozarelix/Placebo;Placebo
16 A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy Completed NCT01275521 Phase 3 BONT-A intra-prostatic injection;Optimized medical BPH treatment
17 Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT00670306 Phase 3 Cetrorelix Pamoate
18 Medical Therapy of Prostatic Symptoms (MTOPS) Completed NCT00021814 Phase 3 Doxazosin;Finasteride
19 Clinical Trial in Males With BPH (Enlarged Prostate) Completed NCT00029822 Phase 3 Alfuzosin (SL770499)
20 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
21 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Completed NCT01139762 Phase 3 Tadalafil;Placebo;Finasteride
22 Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy Completed NCT01566292 Phase 2, Phase 3 BOTOX
23 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
24 Study to Assess the Efficacy of Medi-Tate TIND Device Active, not recruiting NCT02145208 Phase 3
25 Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) Terminated NCT00449150 Phase 3 Cetrorelix;Cetrorelix;Placebo
26 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
27 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
28 A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH). Unknown status NCT00044226 Phase 2 ML-04A
29 Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy Completed NCT00461123 Phase 2 Vardenafil (Levitra, BAY38-9456);Placebo
30 Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00386009 Phase 2 Tadalafil;Placebo
31 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
32 A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Completed NCT00154843 Phase 2 Lycopene
33 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
34 5-Alpha Reductase and Anabolic Effects of Testosterone Completed NCT00475501 Phase 2 Testosterone Enanthate;Finasteride;Testosterone Enanthate;Finasteride
35 Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH) Recruiting NCT02676544 Phase 1, Phase 2
36 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
37 Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams Active, not recruiting NCT02396420 Phase 2
38 Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy Active, not recruiting NCT01446991 Phase 2 Degarelix;Degarelix
39 Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement Not yet recruiting NCT03109925 Phase 2
40 A Study in Men With Benign Prostatic Hyperplasia Terminated NCT01097707 Phase 2 LY500307;Placebo
41 A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806) Terminated NCT00651807 Phase 2 etonogestrel;Placebo
42 Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) Completed NCT01330927 Phase 1 VA106483
43 A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects Completed NCT02615782 Phase 1 CKD-397
44 Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia Recruiting NCT02592473 Phase 1
45 Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours Unknown status NCT02401581
46 Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) Unknown status NCT00256399 Alfuzosin 10 mg
47 Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia Unknown status NCT01781117
48 The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer Unknown status NCT01089881
49 The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients Unknown status NCT01070602
50 Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan Completed NCT01323998 5ARI;AB

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

MalaCards organs/tissues related to Prostatic Hypertrophy:

39
Prostate, Liver, Heart, Breast, Kidney, Smooth Muscle, Appendix

Publications for Prostatic Hypertrophy

Articles related to Prostatic Hypertrophy:

(show top 50) (show all 540)
id Title Authors Year
1
Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies. ( 28593165 )
2017
2
Case-Control Study of Intra-arterial Verapamil for Intraprostatic Anastomoses to Extraprostatic Arteries in Prostatic Artery Embolization for Benign Prostatic Hypertrophy. ( 28506701 )
2017
3
The androgen receptor plays different roles in macrophage-induced proliferation in prostate stromal cells between transitional and peripheral zones of benign prostatic hypertrophy. ( 28694768 )
2017
4
Investigating the link between benign prostatic hypertrophy, BMI and type 2 diabetes mellitus. ( 28433616 )
2017
5
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
6
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. ( 28332240 )
2017
7
Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. ( 28609136 )
2017
8
Inhibitory Activities of Phenolic Compounds Isolated from Adina rubella Leaves Against 5I+-Reductase Associated with Benign Prostatic Hypertrophy. ( 27399661 )
2016
9
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with I+-blockers. ( 27629686 )
2016
10
Re: Stroke Associated with Alpha Blocker Therapy for Benign Prostatic Hypertrophy. ( 27321530 )
2016
11
Kidney transplant complications from undiagnosed benign prostatic hypertrophy. ( 25832848 )
2015
12
The Impact of Medical and Surgical Treatment for Benign Prostatic Hypertrophy on Erectile Function. ( 26438220 )
2015
13
Varicocele: the origin of benign prostatic hypertrophy? Testosterone dosages in the periprostatic plexus. ( 26290288 )
2015
14
Effects of I+-blocker therapy on active duty military and military retirees for benign prostatic hypertrophy on diabetic complications. ( 25735029 )
2015
15
The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. ( 26543428 )
2015
16
Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry. ( 26492588 )
2015
17
Clinical Outcomes of Transurethral Enucleation with Bipolar for Benign Prostatic Hypertrophy. ( 26662662 )
2015
18
Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. ( 25587300 )
2014
19
Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy. ( 25348255 )
2014
20
Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature. ( 24513237 )
2014
21
Tadalafil and benign prostatic hypertrophy. Too risky. ( 24860894 )
2014
22
Bipolar transurethral resection versus monopolar transurethral resection for benign prostatic hypertrophy: a systematic review and meta-analysis. ( 24754254 )
2014
23
Surgical therapy for benign prostatic hypertrophy/bladder outflow obstruction. ( 24744521 )
2014
24
Efficacy of Long-Term Daily Dosage of Alfuzosin 10 mg upon Sexual Function of Benign Prostatic Hypertrophy Patients: Two-Year Prospective Observational Study. ( 25606561 )
2014
25
Re: a phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 25629105 )
2014
26
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. ( 24892642 )
2014
27
Correlation of transrectal and transabodominal ultrasound measurement of transition zone volume with post-operative enucleated adenoma volume in benign prostatic hypertrophy. ( 24876907 )
2013
28
Re: Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 24120797 )
2013
29
Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate. ( 23565707 )
2013
30
A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. ( 23642948 )
2013
31
Alpha-1 adrenergic antagonists in aircrew for the treatment of benign prostatic hypertrophy. ( 23305000 )
2013
32
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. ( 22123290 )
2012
33
Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. ( 23089217 )
2012
34
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( 21962427 )
2011
35
The early days of prostatectomy for benign prostatic hypertrophy. ( 22132481 )
2011
36
Sphaeranthus indicus attenuates testosterone induced prostatic hypertrophy in albino rats. ( 21503998 )
2011
37
Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. ( 21171937 )
2011
38
Effect of Benincasa hispida fruits on testosterone-induced prostatic hypertrophy in albino rats. ( 24688153 )
2010
39
Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy. ( 21221201 )
2010
40
Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. ( 20944533 )
2010
41
Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. ( 20017412 )
2009
42
Acute colonic obstruction due to benign prostatic hypertrophy. ( 19405320 )
2009
43
Transurethral resection of the prostate (TURP)--in the treatment of benign prostatic hypertrophy (BPH) in Mekelle, Ethiopia. ( 19743783 )
2009
44
Increased frequency and nocturia in a middle aged male may not always be due to benign prostatic hypertrophy: a case report. ( 20184712 )
2009
45
Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. ( 20027550 )
2009
46
Characteristic gene expression profiles of benign prostatic hypertrophy and prostate cancer. ( 19639170 )
2009
47
Increased frequency and nocturia in a middle aged male may not always be due to Benign Prostatic Hypertrophy (BPH): a case report. ( 19946479 )
2009
48
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. ( 19576359 )
2009
49
[Oxidative stress in prostate hypertrophy and carcinogenesis]. ( 19644150 )
2009
50
Benign prostatic hypertrophy. ( 19737273 )
2009

Variations for Prostatic Hypertrophy

Expression for Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for Prostatic Hypertrophy

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1 12.32 AR EGF EGFR FGF8 KLK3
2 11.93 EGF EGFR PCNA
3 11.75 AR CYP19A1 EGFR ESR1
4 11.67 ALPP EGF FGF8
5 11.63 AR EGFR KLK3
6
Show member pathways
11.62 AR EGF EGFR KLK3
7
Show member pathways
11.61 AR ESR1 PGR
8
Show member pathways
11.58 AR EGF EGFR ESR1 FGF8 KLK3
9 11.45 EGF EGFR ESR1
10
Show member pathways
11.29 EGF EGFR ESR1 PGR
11
Show member pathways
11.21 AR ESR1 KLK3
12 11 EGF EGFR
13
Show member pathways
10.97 EGF EGFR
14 10.95 EGF EGFR
15 10.67 EGF EGFR
16 10.03 CYP19A1 ESR1
17
Show member pathways
10.01 EGF EGFR

GO Terms for Prostatic Hypertrophy

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.76 EGF EGFR FGF8
2 transcription initiation from RNA polymerase II promoter GO:0006367 9.75 AR ESR1 PGR
3 response to oxidative stress GO:0006979 9.73 EGFR FGF8 PCNA
4 phosphatidylinositol-mediated signaling GO:0048015 9.67 EGF EGFR FGF8
5 phosphatidylinositol phosphorylation GO:0046854 9.65 EGF EGFR FGF8
6 response to estradiol GO:0032355 9.63 EGFR ESR1 PCNA
7 regulation of cell motility GO:2000145 9.61 EGF EGFR
8 positive regulation of DNA repair GO:0045739 9.61 EGFR PCNA
9 positive regulation of mitotic nuclear division GO:0045840 9.6 EGF FGF8
10 activation of phospholipase C activity GO:0007202 9.59 ADRA1A EGFR
11 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.58 EGF EGFR FGF8
12 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.57 EGF EGFR
13 androgen metabolic process GO:0008209 9.55 CYP19A1 ESR1
14 uterus development GO:0060065 9.54 CYP19A1 ESR1
15 response to lipid GO:0033993 9.52 EGFR PCNA
16 negative regulation of ERBB signaling pathway GO:1901185 9.51 EGF EGFR
17 steroid hormone mediated signaling pathway GO:0043401 9.5 AR ESR1 PGR
18 positive regulation of catenin import into nucleus GO:0035413 9.43 EGF EGFR
19 prostate gland growth GO:0060736 9.37 AR CYP19A1
20 morphogenesis of an epithelial fold GO:0060571 9.26 AR EGFR
21 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.16 AR PGR
22 positive regulation of phosphorylation GO:0042327 9.13 AR EGF EGFR
23 mammary gland alveolus development GO:0060749 8.8 AR EGF ESR1

Molecular functions related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.76 AR EGFR ESR1 PCNA
2 protein tyrosine kinase activity GO:0004713 9.65 EGF EGFR FGF8
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 EGF EGFR FGF8
4 ATPase binding GO:0051117 9.58 AR ESR1 PGR
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 EGF EGFR FGF8
6 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
7 enzyme binding GO:0019899 9.35 AR EGFR ESR1 PCNA PGR
8 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.33 AR ESR1 PGR
9 nitric-oxide synthase regulator activity GO:0030235 9.32 EGFR ESR1
10 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Prostatic Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....